Vanderbilt-Ingram Cancer Center

3 marketed · 3 in Phase 3

Quick facts

Founded	1993

Marketed products

Bisphosphonates · Other
Cetuximab (EGFR inhibitor) · Oncology
Cetuximab is a monoclonal antibody that binds to and blocks the epidermal growth factor receptor (EGFR), preventing ligand-induced activation and downstream proliferation signaling in cancer cells.
Copper Cu 64 Dotatate · Oncology
Copper Cu 64 Dotatate is a radioactive imaging agent that binds to somatostatin receptors on neuroendocrine tumor cells, allowing PET visualization and localization of these tumors.

Phase 3 pipeline

cyclosporine ophthalmic emulsion · Ophthalmology
Cyclosporine ophthalmic emulsion works by suppressing the immune system to prevent rejection of transplanted corneal tissue.
Magic Mouthwash · Oncology
Magic Mouthwash is a topical oral rinse that combines local anesthetics, antimicrobials, and anti-inflammatory agents to relieve oral mucositis pain and promote healing in cancer patients.
TGR-1202 · Oncology
TGR-1202 is a selective inhibitor of the PI3K delta subunit.

Phase 2 pipeline

Erlotinb · Other
Hormonal Therapy

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Vanderbilt-Ingram Cancer Center

What are Vanderbilt-Ingram Cancer Center's marketed drugs?

Top marketed products include Bisphosphonates, Cetuximab (EGFR inhibitor), Copper Cu 64 Dotatate.

What is Vanderbilt-Ingram Cancer Center's pipeline?

Vanderbilt-Ingram Cancer Center has 3 drugs in Phase 3, 2 in Phase 2, 2 in Phase 1. Late-stage candidates include cyclosporine ophthalmic emulsion, Magic Mouthwash, TGR-1202.

When was Vanderbilt-Ingram Cancer Center founded?

Vanderbilt-Ingram Cancer Center was founded in 1993.

Bisphosphonates · Other
Cetuximab (EGFR inhibitor) · Oncology
Copper Cu 64 Dotatate · Oncology
Sector hub: All tracked pharma companies